Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK BSE: 532296 SECTOR: Pharmaceuticals & Drugs  142k   1k   201

663.05
+31.55 (5.00%)
NSE: Today, 03:58 PM

Price Summary

Today's High

₹ 664.35

Today's Low

₹ 635.5

52 Week High

₹ 633.5

52 Week Low

₹ 348.5

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

18709.16 Cr.

Enterprise Value

22349.88 Cr.

No. of Shares

28.22 Cr.

P/E

15.48

P/B

1.05

Face Value

₹ 1

Div. Yield

0.4 %

Book Value (TTM)

₹  633.57

CASH

29.63 Cr.

DEBT

3670.35 Cr.

Promoter Holding

46.65 %

EPS (TTM)

₹  42.84

Sales Growth

7.58%

ROE

12.67 %

ROCE

13.25%

Profit Growth

21.12 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Glenmark Pharmaceuticals Ltd.

CANDID ALEX-P SYRUP SIBUTRIM GLINATE LEREZ VORTH-XT STRONAT ERDOZET DYCERIN FINTOP SIBET NITAZET-O ONABET ESOZ - D COLY-MONAS PALNOX AIRTEC-FB BORTRAC GEFTIB TAZRET EVERMIL GLUCAR ZINOX TACROZ FORTE FLEXILOR MIGNAR ASCORIL PLUS TACROZ

Index Presence

The company is present in 23 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year7.58%
3 Year8.9%
5 Year0.38%

Profit Growth

1 Year21.12%
3 Year7.19%
5 Year-1.37%

ROE%

1 Year12.67%
3 Year11.74%
5 Year11.46%

ROCE %

1 Year13.25%
3 Year12.34%
5 Year12.13%

Debt/Equity

0.2193

Price to Cash Flow

15.38

Interest Cover Ratio

10.9027118170148

CFO/PAT (5 Yr. Avg.)

1.04023315553617

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2023 46.65 0
Dec 2022 46.65 0
Sep 2022 46.65 0
Jun 2022 46.65 0
Mar 2022 46.65 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 10.9027118170148.
  • The Company has been maintaining an effective average operating margins of 20.3610695506684% in the last 5 years.
  • Company’s PEG ratio is 0.732898792750012.
  • The company has an efficient Cash Conversion Cycle of -51.0703008849577 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.04023315553617.

 Limitations

  • The company has shown a poor revenue growth of 8.89575227579076% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
Net Sales 1785.54 1911.93 2208.21 2161.47 1939.05
Total Expenditure 1623.96 1478.11 1825.78 1722.63 1721.38
Operating Profit 161.59 433.82 382.43 438.84 217.67
Other Income 178.98 346.52 316.73 89.73 232.97
Interest 74.01 39.76 52.47 55.72 58.86
Depreciation 41.77 45.03 46.17 46.22 46.73
Exceptional Items 0 0 0 162.5 -658.37
Profit Before Tax 224.79 695.55 600.52 589.13 -313.33
Tax 19.19 202.97 177.37 158.62 -175.86
Profit After Tax 205.6 492.58 423.15 430.5 -137.47
Adjusted EPS (Rs) 7.29 17.46 15 15.26 -4.87

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 5520.44 6304.87 6712.63 7567.93 8141.58
Total Expenditure 4419.43 4977.39 5408.4 5677.59 6453.36
Operating Profit 1101 1327.48 1304.23 1890.34 1688.22
Other Income 179.99 475.61 606.79 396.24 614.63
Interest 190.9 223.81 256.39 265.9 236.04
Depreciation 95.93 106.28 138.54 150.82 159.7
Exceptional Items 0 345.19 18.55 73.89 430.33
Profit Before Tax 994.17 1818.18 1534.64 1943.76 2337.45
Tax 128.31 329.88 180.1 294.31 339.66
Net Profit 1014.35 1622.11 1354.55 1649.45 1997.79
Adjusted EPS (Rs.) 30.69 52.74 48 58.46 70.8

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 28.22 28.22 28.22 28.22 28.22
Total Reserves 10363.22 11913.87 13198.05 14781.29 16710.37
Borrowings 2686.03 2831.45 3131.17 3112.58 2571.74
Other N/C liabilities -658.02 -623.63 389.35 1150.51 1412.85
Current liabilities 2184.8 2280.65 2991.54 3934.34 4896.21
Total Liabilities 14604.26 16430.56 19738.33 23006.93 25619.39
Assets
Net Block 1699.12 1413.48 1611.95 1722.49 1752.33
Capital WIP 354.04 209.18 152.5 93.31 101.17
Intangible WIP 65.63 77.02 47.52 38.09 7.87
Investments 3212.68 3268.75 4713.93 6989.95 8559.39
Loans & Advances 3388.72 6306.95 8182.74 7818.27 9335.01
Other N/C Assets 8.8 14.04 2.78 4.72 5.55
Current Assets 5875.25 5141.15 5026.92 6340.11 5858.08
Total Assets 14604.26 16430.56 19738.33 23006.93 25619.39
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 1218.83 2021.02 1534.64 1943.76 2337.45
Adjustment 133.67 -354.75 -107.18 235.11 -617.5
Changes in Assets & Liabilities 63.29 1221.78 491.01 -599.61 -113.17
Tax Paid -292.07 -398.47 -339.35 -335.84 -390.72
Operating Cash Flow 1123.72 2489.58 1579.12 1243.42 1216.07
Investing Cash Flow -1136.98 -2255.53 -1607.41 -1235.19 -897.02
Financing Cash Flow -61.58 -155.11 -139.42 -80.79 -305.12
Net Cash Flow -74.83 78.95 -167.71 -72.57 13.93

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Promoters 46.65 46.65 46.65 46.65 46.65
saldanha family tr... 45.45 45.45 45.45 45.45 45.45
blanche elizabeth ... 0.39 0.39 0.39 0.39 0.39
glenn mario saldan... 0.35 0.35 0.35 0.35 0.35
cherylann maria pi... 0.27 0.27 0.27 0.27 0.27
robin joseph pinto 0.18 0.18 0.18 0.18 0.18
neha saldanha 0.01 0.01 0.01 0.01 0.01
PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Investors 53.35 53.35 53.35 53.35 53.35
qualified institut... - - - - -
hsbc pooled invest... 3.69 3.69 3.69 3.48 2.39
hdfc trustee compa... - - - - -
life insurance cor... 2.40 2.40 2.43 2.93 2.93
ashish dhawan 1.81 1.81 1.81 2.48 2.55
hdfc large and mid... - 2.18 2.36 2.37 2.34
ntasain discovery ... 2.24 2.24 2.30 2.34 2.02
hdfc trustee compa... 2.18 - - - -
aditya birla sun l... - - 2.25 2.27 2.26
aditya birla sun l... - - - - -
government pension... 1.95 1.95 - - -
aditya birla sun l... 1.92 1.95 - - -
hsbc global invest... 1.64 1.64 1.55 1.04 -
life insurance cor... - - - - -
ellipsis partners ... 1.29 1.29 1.32 1.68 1.68
bajaj allianz life... - - - - -
hdfc life insuranc... - - - - -
wgi emerging marke... - - - - 1.22
iepf 0.08 0.08 - - -
investor education... - - - - 0.09
investor education... - - 0.08 0.09 -

Annual Reports

Ratings & Research Reports

Company Presentations

  • PresentationQ3FY19 9 Jan 2020

Company News

Glenmark Pharmaceuticals informs about disclosure of related party transactions20 May 2023, 10:18AM Glenmark Pharma - Quaterly Results19 May 2023, 7:00PM Glenmark Pharma - Quaterly Results19 May 2023, 7:00PM Glenmark Pharmaceuticals incorporates wholly-owned subsidiary15 May 2023, 9:40AM Glenmark to pay $87.5 million to settle lawsuits related to generic drug in US 26 Apr 2023, 12:59PM Glenmark Pharmaceuticals informs about media release23 Mar 2023, 9:55AM Glenmark Pharmaceuticals gets USFDA’s approval for Calcipotriene and Betamethasone Dipropionate Foam23 Mar 2023, 9:18AM Glenmark Pharmaceuticals informs about media release20 Mar 2023, 9:59AM Glenmark Pharmaceuticals gets USFDA’s approval for Prochlorperazine Maleate Tablets 20 Mar 2023, 9:19AM Glenmark Pharmaceuticals’ arm gets USFDA’s approval for GRC 5427616 Mar 2023, 4:51PM Glenmark Pharmaceuticals informs about press release14 Mar 2023, 2:57PM Glenmark Pharmaceuticals gets USFDA’s final nod for Clindamycin Hydrochloride Capsules14 Mar 2023, 11:39AM Glenmark Pharmaceuticals inks pact with Cediprof9 Mar 2023, 10:40AM Glenmark Pharmaceuticals informs about media release9 Mar 2023, 9:41AM Glenmark Pharmaceuticals informs about media release17 Feb 2023, 10:00AM Glenmark Pharmaceuticals’ arm gets second tentative approval for Saxagliptin Tablets17 Feb 2023, 9:42AM Glenmark Pharmaceuticals reports 21% rise in Q3 consolidated net profit13 Feb 2023, 11:52AM Glenmark Pharma - Quaterly Results10 Feb 2023, 7:47PM Glenmark Pharma - Quaterly Results10 Feb 2023, 7:47PM Glenmark Pharmaceuticals informs about update 27 Jan 2023, 9:42AM Glenmark Pharmaceuticals informs about media release23 Jan 2023, 9:49AM Glenmark Pharmaceuticals launches AKYNZEO I.V in India23 Jan 2023, 9:18AM Glenmark Pharmaceuticals enters into agreement with Eris Oaknet Healthcare 17 Jan 2023, 6:06PM Glenmark Pharmaceuticals informs about analyst meet intimation17 Jan 2023, 4:59PM Glenmark Pharmaceuticals informs about press release 17 Jan 2023, 2:42PM Glenmark Pharmaceuticals launches sacubitril + valsartan tablets in India17 Jan 2023, 2:22PM Glenmark Pharmaceuticals informs about media release10 Jan 2023, 9:25AM Glenmark Pharma’s arm launches Bumetanide Injection 10 Jan 2023, 9:19AM Glenmark Pharmaceuticals informs about media release21 Dec 2022, 9:33AM Glenmark Pharmaceuticals launches first triple FDC Teneligliptin with Pioglitazone and Metformin21 Dec 2022, 9:24AM Glenmark Pharmaceuticals informs about press release 19 Dec 2022, 9:38AM Glenmark Pharmaceuticals gets final nod for Nicardipine Hydrochloride Capsules from USFDA19 Dec 2022, 9:22AM Glenmark Pharmaceuticals to divest cardiac brand ‘Razel’ 15 Dec 2022, 10:29AM USFDA issues warning letter to Glenmark Pharma for lapses at Goa plant12 Dec 2022, 10:38AM Glenmark Pharmaceuticals informs about RPT disclosure26 Nov 2022, 12:06PM USFDA issues warning letter to Glenmark Pharmaceuticals’ Goa facility24 Nov 2022, 10:20AM Glenmark Pharmaceuticals informs about media release22 Nov 2022, 9:33AM Glenmark Pharmaceuticals reaches settlement agreement with Pfizer for Axitinib Tablets22 Nov 2022, 9:22AM Glenmark Pharmaceuticals reports marginal rise in Q2 consolidated net profit12 Nov 2022, 2:27PM Glenmark Pharma - Quaterly Results11 Nov 2022, 6:47PM Glenmark Pharma - Quaterly Results11 Nov 2022, 6:47PM Glenmark Pharmaceuticals gets USFDA’s nod for Sodium Phenylbutyrate Tablets 2 Nov 2022, 11:47AM Glenmark Pharmaceuticals informs about press release 2 Nov 2022, 9:36AM Glenmark Pharma’s arm launches Fingolimod Capsules in US1 Nov 2022, 9:37AM Glenmark Pharmaceuticals informs about media release20 Oct 2022, 9:33AM Glenmark becomes first company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination20 Oct 2022, 9:28AM Glenmark becomes first company to launch Lobeglitazone in India for uncontrolled type 2 diabetes in adults6 Oct 2022, 9:20AM Glenmark Pharmaceuticals informs about media release6 Oct 2022, 9:16AM Glenmark Pharmaceuticals informs about media release23 Sep 2022, 9:44AM Glenmark Pharma’s arm launches Ryaltris seasonal allergic rhinitis nasal spray in US1 Sep 2022, 11:14AM

Glenmark Pharma Stock Price Analysis and Quick Research Report. Is Glenmark Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Glenmark Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 1216.067 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Glenmark Pharma has a Debt to Equity ratio of 0.2193 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Glenmark Pharma , the EPS growth was 21.1186913873388 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Glenmark Pharma has OPM of 20.7357882946813 % which is a good sign for profitability.
     
  • ROE: Glenmark Pharma have a average ROE of 12.6723025252642 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Glenmark Pharma

X